View Future GrowthGL Pharm Tech 過去の業績過去 基準チェック /06GL Pharm Techは26.9%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで11.9%毎年増加している。売上は成長しており、年平均23.9%の割合である。主要情報26.87%収益成長率34.96%EPS成長率Pharmaceuticals 業界の成長11.32%収益成長率23.87%株主資本利益率-0.66%ネット・マージン-0.36%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Reported Earnings • Mar 22Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023)Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • Mar 21Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 15Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 14First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesお知らせ • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea分析記事 • Dec 01GL Pharm Tech (KOSDAQ:204840) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Sep 23GL Pharm Tech Corp.'s (KOSDAQ:204840) P/S Still Appears To Be ReasonableWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...New Risk • Aug 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Market cap is less than US$100m (₩90.2b market cap, or US$64.7m).Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.分析記事 • Apr 23Revenues Tell The Story For GL Pharm Tech Corp. (KOSDAQ:204840) As Its Stock Soars 45%The GL Pharm Tech Corp. ( KOSDAQ:204840 ) share price has done very well over the last month, posting an excellent gain...New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩5.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩109.2b market cap, or US$76.8m).Reported Earnings • Mar 22Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023)Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.お知らせ • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South KoreaNew Risk • Aug 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.8b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.8b free cash flow). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩80.8b market cap, or US$60.4m).分析記事 • Jul 23Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Apr 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩101.2b market cap, or US$73.6m).New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩104.5b market cap, or US$77.7m).Reported Earnings • Mar 21Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 07W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity FundW Science Co., Ltd. agreed to acquire a 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund for KRW 15.77 billion on September 14, 2023. W Science Co., Ltd. entered into an agreement to acquire 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund, KAIS Inc and Hoon-sik Wang for KRW 15.77 billion on February 28, 2024. The offer per share is KRW 1700 per share. The scheduled transaction closing date is April 29, 2024. W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund on March 6, 2024.お知らせ • Mar 06GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd.On March 6, 2024, GL Pharm Tech Corp. closed the transaction.分析記事 • Mar 01Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% HigherGL Pharm Tech Corp. ( KOSDAQ:204840 ) shares have had a really impressive month, gaining 25% after a shaky period...Reported Earnings • Nov 15Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.New Risk • Nov 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩3.1b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.1b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$59.9m).New Risk • Jul 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩67.7b market cap, or US$52.6m).Reported Earnings • May 14First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 08Third quarter 2022 earnings released: ₩5.00 loss per share (vs ₩5.00 loss in 3Q 2021)Third quarter 2022 results: ₩5.00 loss per share (in line with 3Q 2021). Revenue: ₩4.70b (up 88% from 3Q 2021). Net loss: ₩306.2m (loss narrowed 78% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.分析記事 • Mar 30Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Dec 15The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding OnPassive investing in index funds can generate returns that roughly match the overall market. But one can do better than...Is New 90 Day High Low • Dec 02New 90-day high: ₩1,190The company is up 17% from its price of ₩1,015 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.お知らせ • Nov 25GL Pharm Tech Corp. announced that it expects to receive KRW 4.5 billion in funding from Ideal Priavate Equity 1 Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of series 6 non-guaranteed private equity convertible bonds with registered interest for gross proceeds of KRW 4,500,000,000 on November 23, 2020. The transaction will include participation from Ideal Priavate Equity 1 Co., Ltd. The bonds will have interest rate of 4% and surface to interest rate 2% and will mature on November 29, 2025. The bonds to be issued are 100% convertible into 4,950,495 shares at a price of KRW 909 for 10.49% equity during the period November 30, 2021 to November 29, 2025. The subscription date is November 23, 2020 and payment date is November 30, 2020. The security to be issued in the transaction will be subject to hold period of one year. The transaction has been approved by the board of directors of the company.Is New 90 Day High Low • Oct 30New 90-day low: ₩875The company is down 14% from its price of ₩1,020 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.お知らせ • Sep 30GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd.On September 29, 2020, GL Pharm Tech Corp. (KOSDAQ:A204840) closed the transaction.Is New 90 Day High Low • Sep 24New 90-day low: ₩896The company is down 10.0% from its price of ₩992 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.お知らせ • Sep 22GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of 1,152,074 common of par value KRW 100 per share, at an issue price of KRW 868 per share for gross proceeds of KRW 1,000,000,232 on September 21, 2020. The transaction will include participation from Kyperion Co., Ltd for all the shares in the transaction. The company will raise the funding through third party allocation method. The total number of shares issued before the transaction is 46,058,145 shares. All securities to be issued in the transaction will be subject to a lock-up period of one year. The transaction was approved by the bard of directors of the company, and is expected to close on September 29, 2020. The securities are issued at 10% per discount.収支内訳GL Pharm Tech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A204840 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2636,862-13212,3491,56631 Dec 2535,2681211,6071,91630 Sep 2534,29930711,2232,58230 Jun 2529,4455710,5571,60931 Mar 2528,053-6819,6391,75431 Dec 2426,048-2,3379,1572,32530 Sep 2424,900-3,4189,0722,04830 Jun 2427,909-4,2648,6092,86231 Mar 2426,761-4,7838,9723,14631 Dec 2326,033-3,7499,0122,37730 Sep 2325,081-2,3898,0412,43730 Jun 2322,095-1,6797,3602,30631 Mar 2319,3257975,9871,88331 Dec 2216,729-7905,6841,96830 Sep 2214,466-1,6025,0032,39630 Jun 2212,271-2,7574,7282,79631 Mar 2211,942-4,5024,4542,73231 Dec 2112,426-3,7273,1902,97430 Sep 2111,652-4,0823,3402,38330 Jun 2111,725-3,3713,1322,18931 Mar 2112,182-3,5993,0702,68431 Dec 2011,988-3,3563,1042,51830 Sep 209,630-3,6482,4292,66630 Jun 209,772-4,1802,5002,48731 Mar 2010,029-6,9672,4722,29631 Dec 1910,608-5,5152,4882,22130 Sep 1912,226-5,5052,7752,01430 Jun 1910,911-5,8443,1701,53831 Mar 199,668-3,3692,9381,81731 Dec 187,998-5,3503,2951,68030 Sep 186,487-4,6192,8581,72030 Jun 185,446-4,1052,1542,13831 Mar 183,826-4,3102,1181,55031 Dec 172,414-4,2371,4661,459質の高い収益: A204840は現在利益が出ていません。利益率の向上: A204840は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A204840は利益を出していないが、過去 5 年間で年間26.9%の割合で損失を削減してきた。成長の加速: A204840の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A204840は利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 20.4% ) と比較することは困難です。株主資本利益率高いROE: A204840は現在利益が出ていないため、自己資本利益率 ( -0.66% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/29 22:23終値2026/05/29 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GL Pharm Tech Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 22Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023)Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • Mar 21Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 15Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 14First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea
分析記事 • Dec 01GL Pharm Tech (KOSDAQ:204840) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Sep 23GL Pharm Tech Corp.'s (KOSDAQ:204840) P/S Still Appears To Be ReasonableWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...
New Risk • Aug 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Market cap is less than US$100m (₩90.2b market cap, or US$64.7m).
Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
分析記事 • Apr 23Revenues Tell The Story For GL Pharm Tech Corp. (KOSDAQ:204840) As Its Stock Soars 45%The GL Pharm Tech Corp. ( KOSDAQ:204840 ) share price has done very well over the last month, posting an excellent gain...
New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩5.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩109.2b market cap, or US$76.8m).
Reported Earnings • Mar 22Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023)Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.
お知らせ • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea
New Risk • Aug 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.8b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.8b free cash flow). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩80.8b market cap, or US$60.4m).
分析記事 • Jul 23Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Apr 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩101.2b market cap, or US$73.6m).
New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩104.5b market cap, or US$77.7m).
Reported Earnings • Mar 21Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 07W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity FundW Science Co., Ltd. agreed to acquire a 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund for KRW 15.77 billion on September 14, 2023. W Science Co., Ltd. entered into an agreement to acquire 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund, KAIS Inc and Hoon-sik Wang for KRW 15.77 billion on February 28, 2024. The offer per share is KRW 1700 per share. The scheduled transaction closing date is April 29, 2024. W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund on March 6, 2024.
お知らせ • Mar 06GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd.On March 6, 2024, GL Pharm Tech Corp. closed the transaction.
分析記事 • Mar 01Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% HigherGL Pharm Tech Corp. ( KOSDAQ:204840 ) shares have had a really impressive month, gaining 25% after a shaky period...
Reported Earnings • Nov 15Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
New Risk • Nov 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩3.1b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.1b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$59.9m).
New Risk • Jul 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩67.7b market cap, or US$52.6m).
Reported Earnings • May 14First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 08Third quarter 2022 earnings released: ₩5.00 loss per share (vs ₩5.00 loss in 3Q 2021)Third quarter 2022 results: ₩5.00 loss per share (in line with 3Q 2021). Revenue: ₩4.70b (up 88% from 3Q 2021). Net loss: ₩306.2m (loss narrowed 78% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
分析記事 • Mar 30Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Dec 15The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding OnPassive investing in index funds can generate returns that roughly match the overall market. But one can do better than...
Is New 90 Day High Low • Dec 02New 90-day high: ₩1,190The company is up 17% from its price of ₩1,015 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
お知らせ • Nov 25GL Pharm Tech Corp. announced that it expects to receive KRW 4.5 billion in funding from Ideal Priavate Equity 1 Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of series 6 non-guaranteed private equity convertible bonds with registered interest for gross proceeds of KRW 4,500,000,000 on November 23, 2020. The transaction will include participation from Ideal Priavate Equity 1 Co., Ltd. The bonds will have interest rate of 4% and surface to interest rate 2% and will mature on November 29, 2025. The bonds to be issued are 100% convertible into 4,950,495 shares at a price of KRW 909 for 10.49% equity during the period November 30, 2021 to November 29, 2025. The subscription date is November 23, 2020 and payment date is November 30, 2020. The security to be issued in the transaction will be subject to hold period of one year. The transaction has been approved by the board of directors of the company.
Is New 90 Day High Low • Oct 30New 90-day low: ₩875The company is down 14% from its price of ₩1,020 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
お知らせ • Sep 30GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd.On September 29, 2020, GL Pharm Tech Corp. (KOSDAQ:A204840) closed the transaction.
Is New 90 Day High Low • Sep 24New 90-day low: ₩896The company is down 10.0% from its price of ₩992 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.
お知らせ • Sep 22GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of 1,152,074 common of par value KRW 100 per share, at an issue price of KRW 868 per share for gross proceeds of KRW 1,000,000,232 on September 21, 2020. The transaction will include participation from Kyperion Co., Ltd for all the shares in the transaction. The company will raise the funding through third party allocation method. The total number of shares issued before the transaction is 46,058,145 shares. All securities to be issued in the transaction will be subject to a lock-up period of one year. The transaction was approved by the bard of directors of the company, and is expected to close on September 29, 2020. The securities are issued at 10% per discount.